Lisanti Capital Growth LLC Grows Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Lisanti Capital Growth LLC raised its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 80.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 26,910 shares of the specialty pharmaceutical company's stock after buying an additional 11,990 shares during the quarter. Lisanti Capital Growth LLC owned about 0.13% of ANI Pharmaceuticals worth $1,488,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ANIP. State of Alaska Department of Revenue increased its stake in shares of ANI Pharmaceuticals by 5.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 9,467 shares of the specialty pharmaceutical company's stock worth $564,000 after acquiring an additional 464 shares in the last quarter. New York State Teachers Retirement System increased its stake in shares of ANI Pharmaceuticals by 1.7% during the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company's stock valued at $1,439,000 after purchasing an additional 394 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of ANI Pharmaceuticals by 6.9% during the third quarter. Principal Financial Group Inc. now owns 89,961 shares of the specialty pharmaceutical company's stock valued at $5,367,000 after purchasing an additional 5,829 shares in the last quarter. Summit Global Investments lifted its holdings in shares of ANI Pharmaceuticals by 154.2% during the third quarter. Summit Global Investments now owns 19,704 shares of the specialty pharmaceutical company's stock valued at $1,176,000 after purchasing an additional 11,952 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its position in shares of ANI Pharmaceuticals by 153.6% in the 3rd quarter. Victory Capital Management Inc. now owns 12,919 shares of the specialty pharmaceutical company's stock worth $771,000 after purchasing an additional 7,825 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company's stock.

Remove Ads

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP traded up $2.59 during trading on Tuesday, reaching $61.40. 430,198 shares of the company traded hands, compared to its average volume of 230,754. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a 50 day simple moving average of $57.86 and a 200-day simple moving average of $58.07. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.81. The stock has a market capitalization of $1.29 billion, a PE ratio of -111.64 and a beta of 0.63.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now directly owns 66,525 shares of the company's stock, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Stephen P. Carey sold 7,500 shares of the business's stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the sale, the chief financial officer now owns 154,468 shares of the company's stock, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,300 shares of company stock worth $644,869 in the last ninety days. Insiders own 12.70% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on ANIP shares. Leerink Partnrs raised ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. Leerink Partners started coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an "outperform" rating and a $80.00 price target for the company. Guggenheim upped their price target on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. StockNews.com downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, March 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $79.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.